Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients
- Authors
- Hwang, I. G.; Jang, J. S.; Do, J. H.; Kang, J. H.; Lee, G. W.; Oh, S. Y.; Kwon, H. C.; Jun, H. J.; Lim, H. Y.; Lee, S.; Chi, K. C.; Lee, S. J.
- Issue Date
- Oct-2011
- Publisher
- SPRINGER
- Keywords
- Advanced biliary tract adenocarcinoma; ERCC1; Cisplatin; Oxaliplatin
- Citation
- CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.68, no.4, pp 935 - 944
- Pages
- 10
- Journal Title
- CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Volume
- 68
- Number
- 4
- Start Page
- 935
- End Page
- 944
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/21242
- DOI
- 10.1007/s00280-011-1558-3
- ISSN
- 0344-5704
1432-0843
- Abstract
- Purpose The aim of this study is to evaluate the effect of excision repair cross-complementation group 1 (ERCC1) expression on treatment outcomes in advanced biliary tract adenocarcinoma (ABTA) patients treated with platinum-based chemotherapy. Methods One hundred and six patients with histologically confirmed adenocarcinoma of biliary tract were enrolled at 5 institutions in South Korea between January 2002 and September 2008. Of 106 patients, 93 were assessed by immunohistochemistry from tissue specimens. Sixty-five patients were treated with cisplatin-based regimens and the other 28 treated with oxaliplatin-based ones. Results For total study population, no significant differences were noted in progression-free survival (PFS) and overall survival (OS) between ERCC1-negative and ERCC1-positive patients, respectively (4.2 vs. 2.9 months, p = 0.116; 7.0 vs. 7.8 months, p = 0.143). In patients treated with cisplatin-based regimens, median PFS and OS were significantly longer in ERCC1-negative group than in ERCC1-positive group, respectively (4.6 vs. 1.9 months, p = 0.014; 9.1 vs. 7.9 months, p = 0.017). Disease control rate (DCR) was better in patients with ERCC1 negative than in patients with ERCC1 positive (p = 0.048). On the other hand, in patients treated with oxaliplatin-containing regimens, median PFS and OS tended to be longer in ERCC1-positive group, but these did not reach statistical significances. Response rate was better in patients with ERCC1 positive (p = 0.005). Conclusions ERCC1 shows a significant prognostic value in ABTA patients treated with cisplatin. A survival benefit was observed in ERCC1-negative patients from cisplatin-containing chemotherapy but not from oxaliplatin-containing ones. The action mechanism of ERCC1 on cisplatin may be different from that on oxaliplatin.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/21242)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.